$588M2018 Annual Research Expenditures20th NIH Funding Rank1209Active Externally Funded Investigators15th In research funding among U.S. public institutions
Latest News
-
UAB-developed viral immunotherapy for pediatric brain tumors shows promise
G207, an immunotherapy derived from a modified herpes virus is well tolerated in children with gliomas, and shows signs of clinical effectiveness -
Who will benefit from new ‘game-changing’ weight-loss drug semaglutide?
Get the latest on what UAB’s Timothy Garvey,M.D., calls “a very powerful tool to treat obesity.” -
The tuberculosis pathogen releases its toxin by a novel protein transport system
This transport system may be widespread across many Gram-positive bacteria that contain proteins in the WXG100 superfamily. Tuberculosis kills 1 million people each year. -
Race and poverty appear to guide heart muscle DNA methylation in heart-failure patients
Differences in DNA methylation correlated with differences in heart-failure outcomes, as measured by two-year mortality. -
Spatial mapping of COVID-19 and H1N1 influenza show differential transcriptional signatures
Using spatial transcriptomics, UAB researchers set out to understand the differences and similarities between two viral infections causing acute lung injury, as it could improve patient care, as well as identify novel therapeutic targets. -
Obesity is associated with poor outcomes in heart failure, but achieving biomarker-based treatment target goals implies good prognosis
Heart failure is a leading cause of death in the United States. Highly effective medications are now available, and the disease is manageable if patients seek care and take their prescribed medications regularly.
